| Company Name: |
Foshan Heshuo Pharm technology Co., ltd
|
| Tel: |
15363639686 |
| Email: |
heshuoyiyao@hotmail.com |
| Products Intro: |
Product Name:N-erucoyl-D-erythro-sphingosylphosphorylcholine-d9 CAS:2342574-51-8
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
| Products Intro: |
Product Name:22:1 SM (d18:1/22:1)-d9 CAS:2342574-51-8
|
|
| | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- Basic information |
| Product Name: | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- | | Synonyms: | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)-;22:1 SM (d18:1/22:1)-d9;N-erucoyl-D-erythro-sphingosylphosphorylcholine-d9 | | CAS: | 2342574-51-8 | | MF: | C45H89N2O6P | | MW: | 785.19 | | EINECS: | | | Product Categories: | | | Mol File: | 2342574-51-8.mol | ![3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- Structure](CAS/20211123/GIF/2342574-51-8.gif) |
| | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- Chemical Properties |
| storage temp. | -20°C | | form | solution |
| WGK Germany | WGK 2 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Acute Tox. 3 Dermal Acute Tox. 3 Inhalation Acute Tox. 3 Oral Carc. 2 Eye Irrit. 2 Flam. Liq. 2 Skin Irrit. 2 STOT SE 1 STOT SE 3 |
| | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- Usage And Synthesis |
| Uses | 22:1 SM (d18:1/22:1)-d9 is deuterium labeled 22:1 SM (d18:1/22:1). | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. DOI:10.1080/02688697.2018.1500521 |
| | 3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)- Preparation Products And Raw materials |
|
|
Tag:3,5-Dioxa-8-aza-4-phosphatriacont-21-en-1-aminium, 4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-tri(methyl-d3)-9-oxo-, inner salt, 4-oxide, (7S,21Z)-(2342574-51-8)
Related Product Information
|